⚠ FACILITY DIRECTIVE: B2B INDUSTRIAL API SUPPLY ONLY
Let’s establish the baseline: our facility operates exclusively as a primary biochemical manufacturer of Active Pharmaceutical Ingredients (APIs). The Bupivacaine raw material discussed on this page is strictly synthesized for pharmaceutical R&D, advanced formulation scaling, and commercial generic manufacturing. We are a raw material supplier. We do not manufacture, package, or distribute finished clinical injectables or retail dosage forms.
Advanced Formulation Engineering
Why Standard Bupivacaine API Fails in Extended-Release Liposomal Formulations (And How We Solve It)
The industry is moving past standard epidural solutions. The future of post-surgical analgesia belongs to 72-hour extended-release liposomal matrices. But formulation scientists are quickly discovering a hard truth: you cannot simply force generic, off-the-shelf Bupivacaine powder into a complex lipid bilayer and expect it to stabilize.
Local anesthetics like Bupivacaine (CAS 2180-92-9 for Base, CAS 18010-40-7 for HCl) have been the gold standard for decades. However, as pharmaceutical pipelines shift toward multi-vesicular liposomes and sustained-release microspheres to combat the opioid crisis, procurement desks are hitting a wall. We watch formulators struggle with poor encapsulation efficiency, sudden API dumping, and severe lipid oxidation. The culprit is rarely the formulation protocol—it is almost always the physical and stereochemical properties of the starting API.
The Physical Bottleneck: Particle Size Distribution (PSD) and Polymorphism
Let’s talk about the reality of the factory floor. When you buy standard bulk Bupivacaine from a chemical broker, you are usually receiving a coarsely milled powder with a wildly inconsistent Particle Size Distribution (PSD). In a simple aqueous injectable, this isn't a dealbreaker. But in a liposomal suspension, oversized crystals act like microscopic needles, physically rupturing the lipid vesicles during compounding.
Furthermore, uncontrolled crystallization during cheap manufacturing leads to unstable polymorphs. When these polymorphs transition inside your formulation, they alter the solubility kinetics, causing premature release (dose dumping). By employing advanced micronization and controlled-cooling crystallization, we engineer our Bupivacaine API to maintain a strict, uniform micron-level PSD and an absolute stable polymorphic phase, ensuring seamless integration into complex delivery systems.
The Chemical Threat: Residual Solvents and Chiral Toxicity
Extended-release means the API remains localized in the patient's tissue for up to 72 hours. This amplifies the toxicity risk of any synthetic impurities. Trace heavy metals or residual organic solvents from substandard synthesis will trigger lipid peroxidation, destroying your liposomal matrix from the inside out. Our cGMP-aligned purification protocols aggressively strip these residuals far below USP/EP pharmacopeial limits. Whether your pipeline requires the standard racemic mixture or the highly purified Levobupivacaine (the S-enantiomer) to bypass cardiotoxic risks, we provide an uncompromised, structurally validated raw material.
Audited Release Specifications for Formulation Engineers
| Product Category | Bupivacaine Base / Bupivacaine HCl (Local Anesthetic API) |
|---|
| CAS Registry Number | 2180-92-9 (Base) / 18010-40-7 (HCl) |
|---|
| Chromatographic Purity | ≥ 99.5% (Via HPLC) |
|---|
| Residual Solvents & Moisture | Strictly conforming to, or exceeding, USP/EP monographs. |
|---|
| Particle Size / Morphology | Customizable micronization available for liposomal/microsphere encapsulation. |
|---|
From the Lab Bench: API Sourcing FAQ
+ Should we source Bupivacaine Base or Hydrochloride (HCl) for liposomes?
It depends entirely on your lipid matrix and internal aqueous core pH. Standard aqueous injectables overwhelmingly utilize the highly soluble HCl salt. However, advanced multivesicular liposomes (such as those mimicking Exparel® formulations) typically require the Bupivacaine Base due to its specific partition coefficient, allowing it to efficiently load and stabilize within the hydrophobic lipid bilayers. We supply high-purity grades of both.
+ Can you guarantee the API withstands terminal sterilization processes?
Yes. Our API is synthesized to possess absolute thermal stability. Provided your formulation buffers are correctly calibrated, our Bupivacaine raw material will easily withstand standard pharmaceutical autoclaving (terminal sterilization at 121°C) without undergoing chemical degradation or loss of potency.
+ Do you provide full PSD and XRD data prior to bulk ordering?
We don't expect R&D teams to fly blind. Upon request, we provide comprehensive technical data packages alongside our Certificates of Analysis (COA). This includes Particle Size Distribution (PSD) metrics via laser diffraction and X-ray Powder Diffraction (XRD) patterns to confirm precise polymorphic structure before you begin scale-up.
Stop Fighting Your Raw Materials.
Secure a direct pipeline to physically stabilized, ultra-pure Bupivacaine API. Talk directly to the manufacturing source that understands the physical chemistry of advanced local anesthetics.
Betty | Senior Independent Site Operations
📧 betty@pharma-sunrise.com💬 WhatsApp: +86 18092760627
